Early Cd4+T Cell Responses Are Associated With Subsequent Cd8+T Cell Responses To An Rad5-Based Prophylactic Prime-Boost Hiv Vaccine Strategy

IntroductionInitial evaluation of a candidate vaccine against HIV includes an assessment of the vaccine's ability to generate immune responses. However, the dynamics of vaccine-induced immune responses are unclear. We hypothesized that the IFN-gamma producing cytotoxic CD8+ (CD8+ IFN-gamma+) T cell responses could be predicted by early IL-2 producing CD4+ (CD4+ IL2+) helper T cell responses, and we evaluated this hypothesis using data from a phase I/II prophylactic HIV vaccine trial. The objective was to assess the dynamics and correlations between CD4+ IL-2+ T cell and CD8+ IFN-gamma+ T cell responses after vaccination with a recombinant adenoviral serotype 5 (rAd5) HIV vaccine.MethodsWe analyzed data from the HVTN 068 HIV vaccine trial, which evaluated the immunogenicity of two different strategies for prime and boost vaccination (rAd5-rAd5 vaccine versus DNA-rAd5) in 66 healthy volunteers. Spearman correlations between immunogenicity markers across time-points were calculated. CD8+ IFN-gamma+ T cell response in the rAd5-rAd5 arm was modeled as a function of CD4+ IL-2+ T cell response and time using mixed effects regression models.ResultsModerate to high correlations (r = 0.48-0.76) were observed in the rAd5-rAd5 arm between the CD4+ IL-2+ T cell response at week 2 and later CD8+ IFN-gamma+ T cell responses (weeks 2-52). Regression models confirmed this relationship with a significant association between the two markers: for a 1.0% increase in CD4+IL-2+T cells at week 2 post-prime, a 0.3% increase in CD8+ IFN-gamma+ T cell responses across subsequent time points, including post-boost time points, was observed (p<0.01).ConclusionThese results suggest an early and leading role of CD4+ T cells in the cellular response to the rAd5-rAd5 vaccine and in particular the stimulation of cytotoxic CD8+ T cell responses. These results could inform better timing of CD4+ T cell measurements in future clinical trials.